Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of chlorpromazine hydrochloride in treatment of endometrial cancer

A kind of endometrial cancer, chlorpromazine hydrochloride technology, applied in the field of medicine

Pending Publication Date: 2022-06-07
THE INT PEACE MATERNITY & CHILD HEALTH HOSPITAL OF CHINA WELFARE INST +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Chlorpromazine hydrochloride is clinically used for the treatment of psychotic drugs, there is no literature report that chlorpromazine hydrochloride can be used for the treatment of endometrial cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chlorpromazine hydrochloride in treatment of endometrial cancer
  • Application of chlorpromazine hydrochloride in treatment of endometrial cancer
  • Application of chlorpromazine hydrochloride in treatment of endometrial cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0085] Example 1 Chlorpromazine hydrochloride against endometrial cancer cells ISK (ISK, type I, progesterone-sensitive), KLE cells (type II, progesterone-resistant), HEC-1A (type II) and AN3CA (type I, Proliferation inhibitory effect of FGFR2 mutation)

[0086] 1.1 Experimental materials and methods

[0087] Endometrial cancer cells ISK, KLE, HEC-1A and AN3CA were purchased from American tissue culture bank ATCC; phosphate buffered saline (PBS) and DMEM / F12 medium were purchased from Hyclone; serum (FBS) was purchased from Gibco Company; Pancreatin and CCK8 were purchased from Biyuntian Biotechnology Co., Ltd.; Chlorpromazine Hydrochloride (CPZ) and Medroxyprogesterone Acetate (MPA) were obtained from the laboratory old drug storehouse. The specific experimental methods are as follows:

[0088] 1) Take the cells in the logarithmic growth phase, pour out the culture medium in the petri dish, and add 2 mL of PBS to wash the cells twice.

[0089] 2) Add 1 mL of trypsin and di...

Embodiment 2

[0099] Example 2 The effect of chlorpromazine hydrochloride and MPA on ISK and KLE cell clone formation

[0100] 2.1 Experimental materials and methods

[0101] Crystal violet was purchased from Biyuntian Biotechnology Co., Ltd.; methanol was a commonly used laboratory reagent and was purchased commercially without any treatment. The sources of other experimental materials are the same as those in Example 1. The specific experimental methods are as follows:

[0102] 1) Take the cells in the logarithmic growth phase, digest them with trypsin to prepare a single-cell suspension, dilute them in a gradient manner, and inoculate them into a 6-well plate at a density of about 800 cells per well, and allow them to adhere overnight.

[0103] 2) Five experimental groups were set up, namely control group; MPA 10 μM group; MPA 20 μM group; CPZ 5 μM group; CPZ 10 μM group; CPZ 20 μM group. The administration group was cultured with 1 mL of DME / F12 medium containing different concentrat...

Embodiment 3

[0112] Example 3 The effect of chlorpromazine hydrochloride and MPA on the migration ability of ISK and KLE cells

[0113] 3.1 Experimental materials and methods

[0114] Paraformaldehyde is a reagent commonly used in the laboratory, purchased commercially, without any treatment, and the sources of all other experimental materials are the same as in Example 1, and the concrete experimental method is as follows:

[0115] 1) Take 100 μL of serum-free ISK / KLE cell suspension (about 200,000 cells) and add it to the upper chamber of the Transwell chamber. The medium used for the cell suspension was serum-free DME / F12 medium.

[0116] 2) Add 600 μL of DME / F12 medium containing 20% ​​FBS to the lower chamber, taking care to avoid the generation of air bubbles.

[0117] 3) Set up 3 experimental groups, namely control group; MPA 5μM group; CPZ 5μM group. 100 μL of serum-free DME / F12 medium containing different drugs was added to the upper chamber of the administration group. 100 μL...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines, in particular to application of chlorpromazine hydrochloride to treatment of endometrial cancer, and the endometrial cancer comprises type I endometrial cancer and type II endometrial cancer. Experiments find that chlorpromazine hydrochloride has an inhibiting effect on proliferation, clone formation and migration ability of endometrial cancer Ishikawa (ISK cells) and KLE cells, can induce apoptosis, up-regulate cell PRB expression, inhibit cell AKT phosphorylation and inhibit growth of subcutaneous transplantation tumors of mice, and is proved to be effective in mouse experiments. Therefore, the invention provides a new application of the antipsychotic drug chlorpromazine hydrochloride in treatment of endometrial cancer.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of chlorpromazine hydrochloride in the treatment of endometrial cancer. Background technique [0002] Endometrial cancer (EC) is one of the malignant tumors of the female reproductive tract worldwide with an increasing incidence (Morice, The Lancet, 2016, 387, 1094–108), and up to 25% of women are Premenopausal onset (Sanderson, Obstetrics, Gynaecology & Reproductive Medicine, 2019, 29, 225-232). According to the American Cancer Society, in 2020, the United States is expected to report 65,620 new EC cases and 12,590 new EC deaths (Siegel, CA: A Cancer Journal for Clinicians, 2020, 70, 7-30). In 2015, there were about 63,400 new EC cases and 21,800 new EC deaths in China (Chen, CA: A Cancer Journal for Clinicians, 2016, 66, 115-132). In recent years, the age of onset of EC in China also tends to be younger (Xu Guorong, Chinese Journal of Misdiagnosis, 2009, Sept...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/5415A61K31/57A61P35/00
CPCA61K31/5415A61K31/57A61P35/00A61K2300/00
Inventor 王玉东崔云霞毛斐孙笑伍慧雯刘小虎李剑
Owner THE INT PEACE MATERNITY & CHILD HEALTH HOSPITAL OF CHINA WELFARE INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com